Stifel Nicolaus analyst Alex Thompson CFA maintained a Hold rating on Aclaris Therapeutics (ACRS – Research Report) on December 19 and set a price target of $1.00. The company’s shares closed yesterday at $0.94.
Thompson CFA covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Argenx Se, and MoonLake Immunotherapeutics. According to TipRanks, Thompson CFA has an average return of 8.9% and a 58.97% success rate on recommended stocks.
Aclaris Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.86.
See Insiders’ Hot Stocks on TipRanks >>
Based on Aclaris Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $9.28 million and a GAAP net loss of $29.26 million. In comparison, last year the company earned a revenue of $19.02 million and had a GAAP net loss of $19.95 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aclaris Therapeutics (ACRS) Company Description:
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
Read More on ACRS:
- Aclaris Therapeutics to reduce workforce by 46%, provides corporate updates
- Aclaris Therapeutics Provides Corporate Update
- Aclaris in alopecia patent license pact with Sun Pharma includes $15M upfront
- Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
- Largest borrow rate increases among liquid names
